Marty Makary’s FDA Voucher Program Faces Overhaul
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- RevMed offers its experimental pancreatic cancer drug daraxonrasib through an expanded access program, but patients still find it difficult to obtain.
- FDA’s voucher program, created under former chief Marty Makary, could be slated for a redesign.
Why it matters: Patients seeking daraxonrasib still confront access barriers, while a potential overhaul of the FDA voucher program could alter the financial incentive structure for biotech firms that count on vouchers for rare‑disease drugs.
